HuMax-CD20

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Chronic Lymphocytic LeukemiaLymphoma, Follicular

Phase 1

Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

WithdrawnNCT00092274

GlaxoSmithKlineLymphoma, Follicular

Start: 2004-09-30End: 2005-01-31Updated: 2015-04-21

HuMax-CD20 in Chronic Lymphocytic Leukemia

WithdrawnNCT00093314

GlaxoSmithKlineChronic Lymphocytic Leukemia

Start: 2004-10-31End: 2007-01-31Updated: 2015-04-21

Related Papers

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

2008-04-04189 citations

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.

2007-11-14272 citations